Urokinase-Receptor (u-PAR)–An Essential Player in Multiple Games of Cancer: A Review on Its Role in Tumor Progression, Invasion, Metastasis, Proliferation/dormancy, Clinical Outcome and Minimal Residual Disease

The relevance of the u-PA system in mediating tumor-associated proteolysis, invasion and metastasis, amongst other phenomena associated with tumor progression, has been clearly demonstrated in diverse cancer entities. This review will update on the biological and clinical relevance of the urokinase-receptor (u-PAR). Specifically, the article focuses on the potential importance of u-PAR for the development of minimal residual disease in solid cancer, and in this context reviews the biological relevance of the u-PAR for tumor cell dormancy. Furthermore, transcriptional mechanisms regulating u-PAR in vitro and in vivo, and their potential clinical and therapeutic relevance in gastrointestinal cancers, are elucidated.

[1]  B. Schwartz,et al.  Interaction of Single-chain Urokinase and Plasminogen Activator Inhibitor Type 1 (*) , 1995, The Journal of Biological Chemistry.

[2]  F. Ali-Osman,et al.  Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. , 1993, Cancer research.

[3]  W. Birchmeier,et al.  Epithelial-mesenchymal transitions in cancer progression. , 1996, Acta anatomica.

[4]  O. Majdic,et al.  Molecular and Functional Characterization of the Urokinase Receptor on Human Mast Cells* , 1997, The Journal of Biological Chemistry.

[5]  B. M. Mueller,et al.  The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae , 1995, The Journal of cell biology.

[6]  H. Höfler,et al.  Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. , 1995, The American journal of pathology.

[7]  F. Blasi,et al.  Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor. , 1994, The Journal of biological chemistry.

[8]  K. Pantel,et al.  Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. , 1996, Journal of the National Cancer Institute.

[9]  Hua Tang,et al.  The Urokinase-type Plasminogen Activator Receptor Mediates Tyrosine Phosphorylation of Focal Adhesion Proteins and Activation of Mitogen-activated Protein Kinase in Cultured Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[10]  G. Sauter,et al.  Expression of Extracellular Matrix Metalloproteases Inducer on Micrometastatic and Primary Mammary Carcinoma Cells , 2004, Clinical Cancer Research.

[11]  J. Izbicki,et al.  Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. , 1994, Journal of hematotherapy.

[12]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[13]  Anne Vincent-Salomon,et al.  Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients , 2004, Clinical Cancer Research.

[14]  H. Allgayer,et al.  Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. , 2000, European journal of biochemistry.

[15]  A. Corti,et al.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[17]  J. Foekens,et al.  Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). , 2002, Cancer research.

[18]  H. Höfler,et al.  Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. , 1995, Cancer research.

[19]  Ruud H. Brakenhoff,et al.  Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.

[20]  S. Capaccioli,et al.  Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. , 1995, Cancer research.

[21]  N. Colburn,et al.  Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Blasi,et al.  Proteolytic cleavage of the urokinase receptor substitutes for the agonist‐induced chemotactic effect. , 1996, The EMBO journal.

[23]  S. Braun,et al.  Biological characteristics of micrometastatic carcinoma cells in bone marrow. , 1996, Current topics in microbiology and immunology.

[24]  W. Schleuning,et al.  Isolation and characterization of urokinase from human plasma. , 1982, The Journal of biological chemistry.

[25]  C. Gondi,et al.  Specific Interference of Urokinase-type Plasminogen Activator Receptor and Matrix Metalloproteinase-9 Gene Expression Induced by Double-stranded RNA Results in Decreased Invasion, Tumor Growth, and Angiogenesis in Gliomas* , 2005, Journal of Biological Chemistry.

[26]  A. Ménez,et al.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide , 2005, The EMBO journal.

[27]  M. Duffy The role of proteolytic enzymes in cancer invasion and metastasis , 1992, Clinical & Experimental Metastasis.

[28]  E. Lengyel,et al.  Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade , 1997, Oncogene.

[29]  H. Verspaget,et al.  Urokinase receptor and colorectal cancer survival , 1994, The Lancet.

[30]  I. Funke,et al.  Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Zhimin Lu,et al.  RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases , 1999, Oncogene.

[32]  D. Boyd Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. , 1989, Cancer research.

[33]  S. Braun,et al.  The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence , 2001, Cancer.

[34]  M. Osborne,et al.  Detection and management of bone marrow micrometastases in breast cancer. , 1994, Oncology.

[35]  Y. Kook,et al.  The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. , 1994, The EMBO journal.

[36]  P. Farnham,et al.  Transcription initiation from the dihydrofolate reductase promoter is positioned by HIP1 binding at the initiation site , 1990, Molecular and cellular biology.

[37]  M. Clark,et al.  Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Allgayer,et al.  Transactivation of the Urokinase-type Plasminogen Activator Receptor Gene through a Novel Promoter Motif Bound with an Activator Protein-2α-related Factor* , 1999, The Journal of Biological Chemistry.

[39]  S. Braun,et al.  Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells , 2004, Histochemistry.

[40]  D. Boyd,et al.  Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene. , 2003, The American journal of pathology.

[41]  T. Reimer,et al.  Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Jian-ning Liu,et al.  Urokinase-type Plasminogen Activator-induced Monocyte Adhesion Requires a Carboxyl-terminal Lysine and cAMP-dependent Signal Transduction (*) , 1995, The Journal of Biological Chemistry.

[43]  D. Easton,et al.  Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. , 1991, European journal of cancer.

[44]  K. Helin,et al.  A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. , 1995, Blood.

[45]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[46]  F. Blasi Surface Receptors for Urokinase Plasminogen Activator , 1988 .

[47]  L. Ossowski,et al.  Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy , 1997, The Journal of cell biology.

[48]  T. Fehm,et al.  Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Izbicki,et al.  Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  T. Urano,et al.  Cancer cells overexpress mRNA of urokinase‐type plasminogen activator, its receptor and inhibitors in human non‐small‐cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization , 1998, International journal of cancer.

[51]  H. Allgayer,et al.  Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules , 1998, Oncogene.

[52]  S. Braun,et al.  Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. , 1996, Progress in histochemistry and cytochemistry.

[53]  J. Millán,et al.  Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[54]  S. Shetty,et al.  Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells , 1997, Molecular and cellular biology.

[55]  C. Gondi,et al.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. , 2006, The Journal of biological chemistry.

[56]  H. Allgayer,et al.  Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2α-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers , 2005, Clinical Cancer Research.

[57]  H. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[58]  C. Zandonella,et al.  Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. , 1996, Cancer research.

[59]  P. Carroll,et al.  Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant , 1998, Cancer.

[60]  H. Allgayer,et al.  Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  H. Sather,et al.  Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. , 1991, The New England journal of medicine.

[62]  G. Cassani,et al.  Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. , 1986, The Journal of biological chemistry.

[63]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[64]  M. Cubellis,et al.  Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.

[65]  H. Petty,et al.  Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. , 1994, Journal of immunology.

[66]  L. Lund,et al.  The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. , 1994, The Journal of investigative dermatology.

[67]  N. Brünner,et al.  Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion , 1994, International journal of cancer.

[68]  H. Petty,et al.  Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. , 1997, Cancer research.

[69]  L. Bolund,et al.  Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. , 1992, American journal of human genetics.

[70]  L. Flohé,et al.  The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[71]  H. Allgayer,et al.  Transcriptional Induction of the Urokinase Receptor Gene by a Constitutively Active Src , 1999, The Journal of Biological Chemistry.

[72]  S. Braun,et al.  Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  D. Boyd,et al.  Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. , 1991, Cancer research.

[74]  P. Carmeliet,et al.  Generation and characterization of urokinase receptor-deficient mice. , 1996, The Journal of clinical investigation.

[75]  E. Appella,et al.  Autocrine saturation of pro-urokinase receptors on human A431 cells , 1986, Cell.

[76]  L. Ossowski,et al.  In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase , 1988, The Journal of cell biology.

[77]  K. Pantel,et al.  RT‐PCR‐Based Detection of Occult Disseminated Tumor Cells in Peripheral Blood and Bone Marrow of Patients with Solid Tumors: An Overview , 2000, Annals of the New York Academy of Sciences.

[78]  D. Boyd,et al.  Requirement of an Upstream AP-1 Motif for the Constitutive and Phorbol Ester-inducible Expression of the Urokinase-type Plasminogen Activator Receptor Gene* , 1996, The Journal of Biological Chemistry.

[79]  D. Boyd,et al.  Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. , 1989, Cancer research.

[80]  H. Höfler,et al.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer , 2005, Breast Cancer Research and Treatment.

[81]  W. Yu,et al.  Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay , 1998, Cell.

[82]  H. Kessler,et al.  Combination of an Src Kinase Inhibitor with a Novel Pharmacological Antagonist of the Urokinase Receptor Diminishes in Vitro Colon Cancer Invasiveness , 2004, Clinical Cancer Research.

[83]  T. Ludwig Local proteolytic activity in tumor cell invasion and metastasis. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[84]  L. Ellis,et al.  Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. , 2005, Cancer research.

[85]  F. Blasi Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[86]  A. Gown,et al.  Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients , 1989, Cancer.

[87]  H. Allgayer,et al.  Immunocytochemical Phenotyping of Disseminated Tumor Cells in Bone Marrow by uPA Receptor and CK18: Investigation of Sensitivity and Specificity of an Immunogold/Alkaline Phosphatase Double Staining Protocol , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[88]  H. Juhl,et al.  Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. , 1997, Cancer research.

[89]  M. Duffy,et al.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer , 1994, The Lancet.

[90]  Kenneth M. Yamada,et al.  Fibronectin at a glance , 2002, Journal of Cell Science.

[91]  N. Brünner,et al.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. , 1994, Cancer research.

[92]  B. Nielsen,et al.  The urokinase receptor as a potential target in cancer therapy. , 2004, Current pharmaceutical design.

[93]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[94]  J. Skibber,et al.  Transcriptional activation of the urokinase receptor gene in invasive colon cancer , 1994, International journal of cancer.

[95]  K. Danø,et al.  Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. , 1986, The Journal of biological chemistry.

[96]  M. Speicher,et al.  Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[97]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[98]  M. Kogo,et al.  Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. , 2005, Oral Oncology.

[99]  A. Niendorf,et al.  Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. , 1997, The New England journal of medicine.

[100]  R. Cote,et al.  Detection of Occult Bone Marrow Micrometastases in Patients with Operable Lung Carcinoma , 1995, Annals of surgery.

[101]  D. Boyd,et al.  The Kruppel-like KLF4 Transcription Factor, a Novel Regulator of Urokinase Receptor Expression, Drives Synthesis of This Binding Site in Colonic Crypt Luminal Surface Epithelial Cells* , 2004, Journal of Biological Chemistry.

[102]  I. Mizukami,et al.  cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. , 1992, Journal of immunology.

[103]  D. Cines,et al.  Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. , 1993, Cancer research.

[104]  J. Köllermann,et al.  Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. , 1995, European journal of cancer.

[105]  H. Allgayer,et al.  Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors , 2007, Oncogene.

[106]  R. Scheuermann,et al.  Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.

[107]  R. Holle,et al.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[108]  K. Preissner,et al.  Urokinase Receptor (CD87) Regulates Leukocyte Recruitment via β2 Integrins In Vivo , 1998, The Journal of experimental medicine.

[109]  Christian Röder,et al.  The detection of disseminated tumor cells in bone marrow from colorectal‐cancer patients by a cytokeratin‐20‐specific nested reverse‐transcriptase‐polymerase‐chain reaction is related to the stage of disease , 1996, International journal of cancer.

[110]  B. Nielsen,et al.  An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator , 1993, FEBS letters.

[111]  K. Pantel,et al.  Prognostic significance of bone marrow micrometastases in patients with gastric cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  Klaus Pantel,et al.  Molecular signature associated with bone marrow micrometastasis in human breast cancer. , 2003, Cancer research.

[113]  H. Allgayer,et al.  Urokinase system expression in gastric carcinoma , 2006, Cancer.

[114]  H. Allgayer,et al.  Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.

[115]  H. Nekarda,et al.  Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  G Kvalheim,et al.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  S. Mandriota,et al.  Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[118]  G. Schlimok,et al.  Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients , 1992, The Lancet.

[119]  P. Jones,et al.  Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases. , 2000, Biochemical and biophysical research communications.

[120]  C. Murray Tumour dormancy: not so sleepy after all , 1995, Nature Medicine.

[121]  D. Belin,et al.  Concomitant secretion of prourokinase and of a plasminogen activator- specific inhibitor by cultured human monocytes-macrophages , 1984, The Journal of experimental medicine.

[122]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  E. Appella,et al.  Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. , 1992, The Journal of biological chemistry.

[124]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[125]  H. Allgayer,et al.  Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis , 1999, British Journal of Cancer.

[126]  H. Allgayer Molecular regulation of an invasion-related molecule--options for tumour staging and clinical strategies. , 2006, European journal of cancer.

[127]  H. Verspaget,et al.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. , 1993, Gut.

[128]  J. Köllermann,et al.  Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer , 1999, International journal of cancer.

[129]  L. Ossowski,et al.  Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling , 1999, The Journal of cell biology.

[130]  L. Lund,et al.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. , 1995, The Biochemical journal.

[131]  K. Pantel,et al.  Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. , 2005, Biochimica et biophysica acta.

[132]  M. Ploug,et al.  Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy. , 2001, Biochemical Society transactions.

[133]  J. Köllermann,et al.  Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[134]  K. Danø,et al.  The Plasminogen Activation System in Human Colon Cancer : Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor , 2006 .

[135]  R. Scheuermann,et al.  Cancer dormancy: isolation and characterization of dormant lymphoma cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[136]  E. Lengyel,et al.  β3A-Integrin Downregulates the Urokinase-Type Plasminogen Activator Receptor (u-PAR) through aPEA3/ets Transcriptional Silencing Element in the u-PAR Promoter , 2001, Molecular and Cellular Biology.

[137]  J. Cajot,et al.  The role of the urokinase receptor in extracellular matrix degradation by ht29 human colon carcinoma cells , 1993, International journal of cancer.

[138]  V. Drewett,et al.  The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism , 2001, Oncogene.

[139]  Bjørn Naume,et al.  Circulating and disseminated tumor cells. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  A. Vaheri,et al.  Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts , 1988, The Journal of cell biology.

[141]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[142]  M L Lesser,et al.  Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  M. L. Le Beau,et al.  Structure of the gene for human plasminogen activator inhibitor-2. The nearest mammalian homologue of chicken ovalbumin. , 1989, The Journal of biological chemistry.

[144]  G. Schlimok,et al.  Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  B. Ljung,et al.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. , 1994, Cancer research.

[146]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.